The relationship between urothelial bladder cancer and high-risk human papillomaviruses (HR-HPV) is still a poorly understood entity, even if some studies have supposed a probably correlation. The aim of the present study was to assess the potential relationship between the presence of HR-HPV and non-muscle invasive urothelial bladder cancers (NMIBC). One hundred and thirty-seven subjects (78 patients affected by NMIBC and 59 controls) were recruited in this prospective study. HR-HPV DNA was evaluated both in urine and tumour tissues. Data from patients were compared with data from controls. The relationship between patients and controls, in terms of HR-HPV presence was performed. The relationship between all pathological data and HR-HPV presence in patient group was carried out. HR-HPV DNA in tissue was found in 27 of 78 (34.6%) tumour samples and in 6 of 59 (10.1%) specimens from TUR-P, with a statistically significant difference (p=0.0009; dF=1; 2 =10.98). HR-HPV DNA in urine was found in 36 of 78 (46.1%) samples obtained from patients, whereas in only 8 of 59 (13.5%) samples from controls (p<0.0001: dF=1; 2 =16.37). A statistical significant difference in terms of HR-HPV frequency between high-grade and low-grade urothelial bladder cancer, was found (p=0.032; RR=0.52 -95% CI 0.27-0.93; OR=0.34 -95% CI 0.13-0.90). In conclusion, this study highlights the correlation between urothelial bladder cancer and high-risk type HPV infection, suggesting the potential etiopathogenetic role of HR-HPV in urothelial bladder cancer development.
Introduction
Approximately 67,160 new bladder cancer cases are expected in the United States in 2007 with 13,750 estimated deaths (1) .
Moreover, the high recurrence rate and the percentage of adjuvant intravesical therapy failure contribute to bladder carcinoma becoming a social problem (2) . In addition, following aspects of the urothelial bladder carcinoma natural history are partially unknown: i) whether a genetic factor exists which determines its predisposition (although there are several oncogenes involved), ii) which are the major risk factors involved in its genesis preventing us from putting into practice an effective prevention campaign. Among all etiopathogenetic factors and co-factors that contribute to urothelial bladder cancer development, we focused our attention on the role of human papillomavirus (HPV), which has been considered as a possible aetiologic agent (3) . HPV is one of the most common sexually transmitted infections worldwide and it is associated with lesions ranging from benign cutaneous warts to malignancies, like cervical, penile or anal cancers (4) . About 13 different HPV genotypes are associated with malignancy and are referred to as high-risk HPV (HR-HPV) (5, 6) . The oncogenic potential of HR-HPV types lies in the oncoproteins E6 and E7, which bind to and modulate a number of different gene products, in particular, the tumour suppressors p53 and pRb. These interactions lead to a disturbance of cell cycle control and a deficiency in DNA repair, resulting in genomic instability and an increased risk of malignant transformation (7) (8) (9) . Even if, the probable relationship between HPV and urothelial bladder cancer is based on the HPV epithelial tropism and the physical closeness of the bladder with the mucosa that covers the urogenital tract, this relationship is not clear and, then, HPV prevalence in subjects with bladder carcinoma oscillates between 0 and 100% in previous studies (3) . Moreover, Gutiérrez and co-workers, by using a meta-analysis study, stated that the relationship between bladder cancer and HPV depends on the method used and in the literature there are insufficient cases and samples compared to controls and all studies rely on a combination of various microbiological techniques in the same patient and sample, making it difficult to draw any definite conclusion (10) . On the other hand, Jiménez Pacheco et al found a clear association between HPV and the bladder cancer (3), by means of a current literature revision. In our study, we have set forth to get further insights into the possible environmental factor that would act as a co-factor in the development of urothelial bladder cancer. The aim of the present study was to evaluate Sample collection and HPV DNA analysis. A sample of 150-300 ml of early morning, spontaneously voided urine was collected before surgery and sent for HPV DNA analysis. Tumour and tissue samples, obtained from surgery were used for pathological examination. From each control subject, a sample of apparently normal bladder mucosa was taken and sent for HPV DNA analysis. Then, a sample of bladder cancer from patients and a sample of apparently normal bladder mucosa from controls were analysed. Specimens were sent also for HPV DNA analysis without any clinical or pathological reference and analyses were, then, performed in blinded fashion. Each sample was sent for HPV DNA analysis to the Laboratory under refrigerated conditions and with RNAlater storage solutions (Qiagen GmbH, Hilden, Germany), in order to avoid any nucleic acids degradation. All biological analyses have been conducted according with our previous studies (11, 12) .
HPV DNA extraction and amplification. The DNA extraction and purification from all biologic materials was performed by DNeasy Tissue kit (Qiagen GmbH (11, 12) .
HPV genotyping. HPV genotyping has been carried out in accordance with the methods previously described (11, 12 
Statistical analysis.
As null hypothesis, we assumed that there was no difference between patients and controls in terms of HR-HPV DNA presence in urine and tissue samples. Fisher's exact test and ¯2 test were used to assess the significance of all parameters, with p<0.05 accepted as significant. Moreover, the relationship between presence and typing of HPV infection and clinicopathologic features was studied using all analyzable samples. All statistical analyses were performed using StatPlus:mac 5.5.5 for Apple-Macintosh (Analyst Soft, 2001-2009, USA). The present study has been designed as an exploratory study in order to provide adequate, approximate information about variances and correlations needed for analysis of power and sample size for the future full-scale study. Therefore, the sample size calculations were not carried out.
Results
Eighty-three patients and 61 controls were enrolled. However, in 7 of 144 samples, presence of the internal control could not be detected and no amplifiable DNA was found, thus these patients were excluded from the analysis. Finally, 78 patients and 59 controls were analyzed. All patient and control characteristics, and clinical and laboratory data are described in Table I . 
------------------------------------------------Patient and control characteristics p-value -------------------------------------------------

-------------------------------------------------Patient characteristics, pathological and clinical data -------------------------------------------------
-------------------------------------------------Control clinical data -------------------------------------------------Urological diseases TUR-P b 59 (100) -------------------------------------------------
The table shows the patient and control characteristics, clinical and laboratory data.
a Bacillus Calmette-Guérin; b Transurethral resection of the prostate.
- ----------------------------------------------- Table II . Distribution of HPV genotypes among patients and controls. 
------------------------------------------------
(22.2%), 31 (11.1%), 33 (7.4%), 45 (18.6%), 51 (7.4%), 58 (11.1%) and 73 (7.4%).
In the control group, only 6 out of 16 subjects (37.5%) were considered as HR-HPV. The statistical difference between the two groups was significant (p=0.0009; dF=1; 2 =10.98).
Correlations between HR-HPV and clinicopathological factors in bladder cancer patients.
No significant difference in terms of HR-HPV frequency between pTa and pT1 urothelial bladder cancer was found, in tissue sample analysis (p=0.80; RR=1.18 -95% CI 0.60-2.34; OR=1.29 -95% CI 0.47-3.35) (Fig. 1A) . On the other hand, a statistically significant difference in terms of HR-HPV frequency between high-grade and low-grade urothelial bladder cancer, was found (p=0.032; RR=0.52 -95% CI 0.27-0.93; OR=0.34 -95% CI 0.13-0.90) (Fig. 1B) .
No difference between the frequency of HR-HPV DNA detected in tissue and those detected in urine samples, both in patients and controls, was found (p=0.19; p=0.77).
Discussion
Tekin et al, recently, stated that HPV did not seem to be related to the aetiology of bladder tumour due to its low prevalence reported in several previous studies (14) , highlighting the possibility, as observed in cervical cancer studies by PCR, that positive results may be caused by superficial contamination of the tissue with HPV (15). Furthermore, Tekin et al suggested that in order to eliminate the possibility of contamination, future studies must be designed by using in situ PCR techniques, including samples taken from tumour and normal bladder mucosa in the same patient (14) . In the present study, in line with these suggestions, we analyzed samples taken both from tumour and urine, in order to eliminate the possibility of contamination and to demonstrate the feasibility and usefulness of HR-HPV DNA detected in the urine samples. However, in 137 subjects, we found a statistically significant difference in terms of HR-HPV DNA presence both in tumour and urine samples between patients and controls. The finding of HR-HPV DNA in tissue samples obtained from NMIBC patients is not a clear demonstration of the etiologic role of HR-HPV in urothelial bladder cancer development but should be considered a background to plan future studies which can demonstrate this association. The relationship between HR-HPV and bladder cancer is still unclear. Several authors stated that HR-HPV should be considered a co-factor in urothelial bladder cancer development. Therefore, Lopez-Beltran et al (16) and coworkers found a possible additional prognostic value of viral infection in bladder cancer, as reported also by Furihata et al (17) who found a significantly worse survival in HPV DNA positive patients. In addition, we found a statistical significant difference in terms of HR-HPV frequency between high-grade and low-grade urothelial bladder cancer. Several authors reported contrasting results. Moonen and coworkers have, recently, also found a higher infection rate in high-grade tumours (9) . Moreover, the same authors stated that the increase in infection rate in high-grade tumours suggests a relation between tumour grade and high-risk HPV infection (9) . On the other hand, Tenti and co-workers found that the prevalence of HPV 16 and/or HPV 18 infection was significantly higher in low-grade than in high-grade tumours (18) . The relationship between high-grade urothelial bladder cancer and HR-HPV presence should be related, as suggested by Moonen et al (9) , to the fact that HR-HPV types stimulate degradation and deactivation of protein associated with the p53 tumour suppressor gene via the ubiquitin-dependent pathway. In addition, Soulitzis et al reported HPV prevalence of 12% in a group of bladder cancer patients and an interesting correlation between HPV-18 and Arg/Arg genotype of the p53 codon 72 homozygosity (19) . The same authors highlight the role of HPV as a significant factor in the development of a small percent of the tumours (19) . However, several biases related to samples collection and laboratory analysis should be taken into account in interpretation. In bladder cancer group, we have found that HPV 18 was the most frequent type, both in tissue and in urine samples (22.2%). These results are in line with other previous reports (20) . Moreover, we found HPV 45 both in tissue (18.6%) and in urine samples (13.9%). For this reason it could be considered a new emerging pathogen. Finally, the absence of statistical difference between HR-HPV DNA frequency in tumour and urine should be considered an important methodological finding due to the fact that, if the etiologic role of HR-HPV in urothelial bladder cancer development will be demonstrated, this test should be considered in the NMIBC screening. However, several points must be considered: should patients who had the presence of HR-HPV DNA be considered more at risk for developing urothelial bladder cancer and, for this reason, undergo other diagnostic exams, such as urinary cytology or ultrasonography? Should patients in follow-up for previous bladder cancer and positive for the presence of HR-HPV DNA undergo stricter follow-up? Should HR-HPV have a similar role in bladder carcinogenesis as in cervical cancer to plan a future-screening program? However, on the basis of high rate of HPV positivity in NMIBC cases, comparing with control group, the present report supports a probable etiologic role of HPV in bladder carcinogenesis.
In conclusion, the present study highlights the correlation between urothelial bladder cancer and high-risk type HPV infection, suggesting the etiologic role of HR-HPV in urothelial bladder cancer development. Moreover, we hypothesize the feasibility of HPV DNA detection in urine samples as a clinical marker in association with standard clinical factors for planning a more appropriate follow-up schedule in urothelial bladder cancer patients.
